Park Ha Biological Technology is trading 8.5% down at $2.31 in pre-market, with no specific cause established. - The latest listed company release is an October 2 offering announcement; it is context, not a confirmed trigger. - October 9 news described a biotech-sector rally, not a company-specific catalyst. - Broader market indicators are mixed and do not show a strong same-direction decline clearly explaining the move.